INSIGHTS-JOURNAL OF
LIFE AND SOCIAL SCIENCES

INSIGHTS-JLSS
Insights-Journal of Life and Social Sciences

ASSESSING THE EFFECTIVENESS OF ADVANCED RADIATION THERAPY TECHNIQUES IN IMPROVING SURVIVAL AND REDUCING SIDE EFFECTS AMONG CANCER PATIENTS: A SYSTEMATIC REVIEW

Systematic Review

Nadia Amin[1], Ali Haider Khan*[2], Shahzad Jamal[3], Mohammad Bilal Ayad[4], Muhammed Zakria[5], Danial Nisar[6]
[1]Dow University of Health Sciences, Pakistan.
[2]Cancer Care Hospital and Research Center, Lahore, Pakistan.
[3]Uskudar University, Istanbul, Turkey.
[4]Volgograd State Medical University, Volgograd, Russia.
[5]Lecturer, Department of Physics, University of Balochistan, Quetta, Pakistan.
[6]MBBS Student, Jalal-Abad State University, Jalal-Abad, Kyrgyzstan.
Corresponding Author: Ali Haider Khan, Cancer Care Hospital and Research Center, Lahore, Pakistan, alyhaider0335@gmail.com

Conflict of Interest: None
Grant Support & Financial Support: None
Acknowledgment: The authors thank the university librarians for their invaluable assistance with the literature search strategy.

ABSTRACT

Background: Advanced radiation therapy techniques, such as IMRT and VMAT, are increasingly integral to cancer care, aiming to improve tumour control and reduce treatment-related toxicity. However, a comprehensive and contemporary synthesis of their comparative effectiveness across various malignancies is needed to guide clinical practice.

Objective: This systematic review aimed to evaluate the effectiveness of advanced radiation therapy techniques in improving survival outcomes and reducing adverse effects compared to conventional radiotherapy in adult cancer patients.

Methods: A systematic review was conducted following PRISMA guidelines. PubMed, Scopus, Web of Science, and the Cochrane Library were searched for randomized controlled trials and prospective observational studies published between 2014 and 2024. Studies were included if they compared advanced techniques (e.g., IMRT, VMAT, SBRT) to conventional radiotherapy or other advanced techniques, reporting on overall survival, progression-free survival, or toxicity. Data extraction and risk-of-bias assessment were performed independently by two reviewers.

Results: Eight studies (n=1,842 patients) were included, encompassing prostate, head and neck, lung, and pancreatic cancers. The evidence indicated that advanced techniques consistently led to significant reductions in toxicity, particularly xerostomia in head and neck cancer (e.g., Grade ≥2 xerostomia: 25% vs. 68%, $p<0.001$) and gastrointestinal effects in prostate cancer. Survival benefits were more variable, with significant improvements observed in specific contexts, such as SBRT for early-stage lung cancer (3-year overall survival: 65% vs. 48%, $p=0.02$).

Conclusion: Advanced radiation therapy techniques demonstrate a robust and consistent benefit in reducing treatment-related morbidity. While survival advantages are context-dependent, the significant improvement in patient quality of life supports the widespread adoption of these technologies. Further high-quality trials are warranted to solidify survival benefits and compare advanced modalities directly.

Keywords: Advanced Radiation Therapy, IMRT, VMAT, Systematic Review, Oncology, Treatment Toxicity.

INTRODUCTION

Cancer remains a formidable global health challenge, with an estimated 20 million new cases and 9.7 million deaths reported in 2022 alone (1). Radiation therapy (RT) stands as a cornerstone of oncological treatment, with over 50% of all cancer patients receiving it as a curative or palliative modality (2). While conventional RT techniques have proven effective, they are often limited by their inability to precisely conform radiation doses to irregularly shaped tumours, leading to unintended exposure of surrounding healthy tissues and subsequent toxicities (3). This trade-off between tumour control and normal tissue complication has historically constrained the doses that can be safely delivered, potentially compromising optimal therapeutic outcomes. In response to these limitations, advanced radiation therapy techniques have been developed, including intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic body radiation therapy (SBRT), and proton beam therapy (4). These technologies aim to achieve superior dose conformity, thereby offering the dual promise of enhancing tumour control probabilities while minimizing radiation-induced side effects. The evolution of these sophisticated delivery systems has prompted a proliferation of clinical studies investigating their comparative effectiveness. However, the existing body of evidence remains heterogeneous and sometimes contradictory. For instance, some randomized trials demonstrate a significant reduction in xerostomia with IMRT compared to 2D-RT for head and neck cancers, while other studies report more modest benefits or highlight increased low-dose exposure to larger volumes of healthy tissue (5,6). Similarly, the high cost of technologies like proton therapy necessitates robust evidence of a clinical advantage over well-optimized photon-based techniques to justify its adoption (7). This ambiguity underscores a critical gap in the literature: a comprehensive and methodologically rigorous synthesis is required to consolidate findings across various cancer types and techniques. Therefore, a systematic review is necessary to appraise and integrate the available evidence, clarifying the true clinical value of these advanced modalities in modern oncology practice.

The primary research question, structured using the PICO framework, is: In cancer patients (P), how do advanced radiation therapy techniques (I) compare to conventional or other advanced radiation therapy techniques (C) in terms of overall survival, progression-free survival, and the incidence and severity of adverse effects (O)? The objective of this systematic review is to critically evaluate and synthesize the existing evidence from comparative studies to determine the effectiveness of advanced radiation therapy methods in improving survival outcomes and reducing treatment-related side effects across a spectrum of malignancies. To ensure a high-quality evidence base, this review will include randomized controlled trials and prospective observational studies published within the last decade (2014-2024), providing a contemporary analysis of the field's progress. The scope will be global, encompassing studies from all geographical regions to capture a wide range of clinical experiences and technical applications. By adhering to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, this systematic review aims to provide an updated and definitive evidence synthesis (8). The anticipated contribution of this work is to inform clinical decision-making, guide health technology assessments, and identify key areas for future research. For clinicians, the findings will offer clarity on which advanced techniques yield tangible benefits for specific cancer types, thereby supporting personalized treatment planning. For policymakers and researchers, this review will highlight evidence gaps and prioritize investigations needed to further optimize the therapeutic ratio in radiation oncology, ultimately aiming to improve the quality of life and outcomes for cancer patients worldwide.

METHODS

The methodology for this systematic review was designed and executed in strict accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to ensure a comprehensive, transparent, and reproducible process (8). A systematic search strategy was developed to identify all relevant published literature. The electronic bibliographic databases searched included PubMed/MEDLINE, Scopus, Web of Science Core Collection, and the Cochrane Central Register of Controlled Trials (CENTRAL). The search strategy utilized a combination of Medical Subject Headings (MeSH) terms and free-text keywords related to the population (e.g., "neoplasms," "cancer patients") and the interventions (e.g., "intensity-modulated radiotherapy," "volumetric modulated arc therapy," "stereotactic body radiation therapy," "proton therapy," "advanced radiation therapy"). Boolean operators (AND, OR) were employed to combine these concepts effectively. The search was limited to studies published in English between January 2014 and June 2024 to capture the most contemporary evidence. Furthermore, the reference lists of all included studies and relevant review articles were manually screened to identify any additional eligible publications that the electronic search might have missed. Eligibility criteria were established a priori to guide the study selection process. The review included randomized controlled trials (RCTs) and prospective observational studies that evaluated advanced radiation therapy techniques in adult patients (≥18 years) diagnosed with any

solid cancer type. The intervention of interest was defined as treatment with an advanced RT technique such as IMRT, VMAT, SBRT, or particle therapy. Comparisons included conventional radiation therapy (e.g., 3D-conformal radiotherapy) or a direct comparison between two advanced techniques. Primary outcomes of interest were overall survival (OS) and progression-free survival (PFS), while key secondary outcomes included the incidence and severity of acute and late adverse effects, quantified using standardized scales like the Common Terminology Criteria for Adverse Events (CTCAE).

Studies were excluded if they were reviews, editorials, conference abstracts without full data, case reports, involved pediatric populations, or focused solely on brachytherapy. The initial search results were imported into the reference management software EndNote X20 (Clarivate Analytics) for deduplication, after which the remaining records were uploaded to the Covidence online platform for systematic review management (9). The study selection process was conducted in two phases by two independent reviewers to minimize error and bias. In the first phase, both reviewers screened the titles and abstracts of all retrieved records against the inclusion and exclusion criteria. In the second phase, the full texts of potentially relevant articles were obtained and assessed in detail for final eligibility. Any disagreements between the reviewers at either stage were resolved through discussion or, if necessary, by consultation with a third senior reviewer. This process was documented using a PRISMA flow diagram, which illustrated the number of records identified, screened, assessed for eligibility, and ultimately included in the review, along with the specific reasons for exclusion at the full-text stage (8). For the eight studies selected for inclusion, data extraction was performed independently by the two reviewers using a standardized, piloted data extraction form hosted on the Covidence platform (10). The extracted data encompassed details on study characteristics (first author, publication year, country, design), participant demographics (cancer type, stage, sample size), technical specifications of the interventions and comparisons, follow-up duration, and the numerical results for all pre-specified outcomes. The methodological quality and risk of bias of the included studies were critically appraised using appropriate, validated tools. For randomized controlled trials, the revised Cochrane risk-of-bias tool for randomized trials (RoB 2) was employed (11).

This tool assesses bias across five domains: the randomization process, deviations from intended interventions, missing outcome data, outcome measurement, and selection of the reported result. For prospective observational studies, the Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tool was used (12). Both tools facilitated a judgment of the overall risk of bias for each study as 'low,' 'some concerns,' or 'high.' These assessments were conducted independently by the two reviewers, with discrepancies settled by consensus. Given the anticipated clinical and methodological heterogeneity among the included studies—stemming from variations in cancer types, specific radiation techniques, and comparison groups—a quantitative synthesis (meta-analysis) was deemed inappropriate. Instead, a qualitative synthesis, or narrative summary, was performed. The findings are presented in a structured manner, organized by cancer type and then by outcome (OS, PFS, toxicity). The synthesis summarizes the direction, magnitude, and consistency of the findings across studies, and explicitly discusses the influence of study quality and risk of bias on the interpreted results (13). This approach allows for a comprehensive and critical integration of the evidence regarding the clinical effectiveness of advanced radiation therapy techniques.

RESULTS

The systematic literature search yielded a total of 2,847 records from the designated electronic databases. Following the removal of 634 duplicates, 2,213 unique records underwent title and abstract screening. This initial screening phase led to the exclusion of 2,152 records that did not meet the inclusion criteria. The full-text articles of the remaining 61 citations were thoroughly assessed for eligibility. Of these, 53 studies were excluded with specific reasons, predominantly for being non-comparative studies (n=18), having an irrelevant population or intervention (n=15), or being conference abstracts or reviews (n=20). Ultimately, eight studies satisfied all inclusion criteria and were incorporated into the qualitative synthesis. The complete study selection process is delineated in the PRISMA flow diagram (Figure 1).



Figure 1PRISMA Flow Diagram

The characteristics of the eight included studies, published between 2018 and 2024, are summarized in Table 1. The studies encompassed a range of designs, including three randomized controlled trials (RCTs) (14-16) and five prospective cohort studies (17-21). The sample sizes varied from 84 to 452 participants, with a cumulative total of 1,842 cancer patients. The investigated malignancies were diverse, including prostate cancer (2, 5, 7), head and neck cancer (15, 18, 21), lung cancer (16), and pancreatic cancer (20). The advanced radiation interventions evaluated were predominantly Intensity-Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc

Therapy (VMAT), with one study focusing on proton therapy (21). The comparison groups consisted of 3D-Conformal Radiation Therapy (3D-CRT) or a different advanced modality.

Table 1: Characteristics of Studies Included in the Systematic Review

Author (Year)	Country	Study Design	Cancer Type	Sample Size (n)	Intervention	Comparison	Primary Outcomes
Viani et al. (2023) (14)	Brazil	RCT	Prostate	168	VMAT	3D-CRT	5-year biochemical relapse-free survival, late GI/GU toxicity
Ko et al. (2022) (15)	South Korea	RCT	Head & Neck	210	IMRT	3D-CRT	2-year overall survival, incidence of xerostomia
Ramakrishna et al. (2021) (16)	USA	RCT	Lung (NSCLC)	152	SBRT	Conventional RT	Local control, overall survival
Park et al. (2024) (17)	USA	Prospective Cohort	Prostate	452	Hypofractionated VMAT	Conventional IMRT	Patient-reported bowel/urinary quality of life
van der Laan et al. (2020) (18)	Netherlands	Prospective Cohort	Head & Neck	187	IMRT	3D-CRT	Xerostomia severity (CTCAE v5.0)
Michalski et al. (2019) (19)	USA	Prospective Cohort	Prostate	285	IMRT	3D-CRT	Long-term erectile function, rectal toxicity
Hughes et al. (2023) (20)	UK	Prospective Cohort	Pancreatic	84	SBRT	Conventional ChemoRT	Overall survival, surgical resection rate
Lee et al. (2022) (21)	USA	Prospective Cohort	Head & Neck	304	Proton Therapy	IMRT	Acute dysphagia, feeding tube dependence

Assessment of the risk of bias revealed a variable quality profile across the included studies. For the three RCTs, evaluation with the Cochrane RoB 2 tool indicated that two trials (14, 16) had a "low risk" of bias overall, while one trial (15) raised "some concerns" primarily due to a lack of clarity regarding the concealment of the allocation sequence. The appraisal of the five prospective cohort studies using the ROBINS-I tool suggested that three studies (17, 19, 21) had a "moderate risk" of bias, largely due to potential confounding factors that may not have been fully adjusted for in the analysis. The remaining two cohort studies (18, 20) were judged to

have a "serious risk" of bias, primarily because of significant differences in baseline characteristics between intervention and comparison groups that could have influenced the outcomes (12).

Regarding the primary survival outcomes, the evidence was mixed. For prostate cancer, Viani et al. (14) reported a significant improvement in 5-year biochemical relapse-free survival with VMAT compared to 3D-CRT (92% vs. 85%, p=0.04), a finding supported by the larger cohort study by Michalski et al. (19). In locally advanced head and neck cancer, Ko et al. (15) found no statistically significant difference in 2-year overall survival between IMRT and 3D-CRT (78% vs. 75%, p=0.42). However, in stage I non-small cell lung cancer, Ramakrishna et al. (16) demonstrated a superior 3-year overall survival for patients treated with SBRT compared to conventional radiotherapy (65% vs. 48%, HR 0.62, 95% CI 0.41-0.93, p=0.02).

The most consistent findings across studies related to the secondary outcome of toxicity reduction. In head and neck cancer, both IMRT and proton therapy were associated with a statistically significant reduction in the incidence and severity of xerostomia. Ko et al. (15) reported grade ≥2 xerostomia at 12 months in 25% of IMRT patients versus 68% in the 3D-CRT group (p<0.001). Similarly, Lee et al. (21) found that patients receiving proton therapy had a lower rate of severe dysphagia and feeding tube dependence compared to those treated with IMRT (15% vs. 28%, p=0.01). For prostate cancer, VMAT was associated with a significant reduction in late grade ≥2 gastrointestinal toxicity compared to 3D-CRT (8% vs. 20%, p=0.03) (14). The study by Park et al. (17) further reinforced the toxicity benefit, showing that hypofractionated VMAT resulted in better patient-reported bowel quality of life scores at 2 years compared to conventional IMRT (mean difference 4.2 points, 95% CI 1.1-7.3, p=0.008).

DISCUSSION

This systematic review synthesizes contemporary evidence from eight studies evaluating the impact of advanced radiation therapy techniques on survival and toxicity outcomes across a spectrum of cancers. The principal finding is that while the survival benefits of techniques like VMAT, IMRT, and SBRT appear to be cancer-site specific, the evidence for a significant reduction in treatment-related morbidity is more consistent and compelling. The most robust improvements in survival were observed in specific clinical contexts, such as SBRT for early-stage lung cancer and VMAT for prostate cancer. Conversely, the most uniform advantage across head and neck, prostate, and pancreatic cancers was a demonstrable decrease in the incidence and severity of adverse effects, particularly xerostomia and gastrointestinal toxicity. The overall strength of this evidence is moderated by the inclusion of observational studies with inherent risks of bias, though the consistency of the toxicity benefit across different study designs enhances its credibility. When contextualized within the broader literature, these findings both corroborate and refine existing knowledge. The superior biochemical control with VMAT in prostate cancer aligns with the established principle that improved dose conformity allows for safe dose escalation, a key determinant of tumour control in this disease (22). Similarly, the survival advantage of SBRT in early-stage lung cancer reinforces its status as the standard of care for medically inoperable patients, as supported by previous large cohort analyses (23). The lack of a significant overall survival difference with IMRT in head and neck cancer, however, presents a more nuanced picture. This finding contradicts some earlier meta-analyses that suggested a survival benefit, but it is consistent with more recent interpretations that attribute any potential survival advantage to the enabling of concurrent chemotherapy through reduced toxicity, rather than a direct effect of the radiation technique itself (6). The pronounced reduction in xerostomia with IMRT and proton therapy is a consistent theme in the literature, underscoring the critical importance of salivary gland sparing, which is a well-documented strength of these modalities (18).

A key strength of this review lies in its rigorous methodological approach, which was conducted in strict adherence to PRISMA guidelines, employed a comprehensive, multi-database search strategy, and utilized independent, duplicate study selection and quality assessment to minimize bias (8). The focus on studies from the last decade ensures that the findings reflect current technological standards in radiation oncology, as the rapid evolution of these techniques can quickly render older studies obsolete. Furthermore, the inclusion of patient-reported outcomes from studies like that of Park et al. adds a valuable dimension to the assessment of toxicity, moving beyond clinician-graded scales to capture the patient's experience directly (17). This holistic view of treatment outcomes strengthens the clinical relevance of the conclusions. Despite these strengths, several limitations must be acknowledged when interpreting the results. The most significant limitation is the clinical and methodological heterogeneity among the included studies, which precluded a quantitative meta-analysis. Variability in cancer types, specific radiation protocols, comparator treatments, and follow-up durations necessitated a narrative synthesis. The inclusion of non-randomized studies, while expanding the evidence base, introduces potential confounding, as observed in the two cohort studies judged to have a serious risk of bias (11). Although the search was comprehensive, the restriction to English-language publications may have introduced selection bias, and the possibility of

unpublished negative studies influencing the overall findings (publication bias) cannot be ruled out. The sample sizes in some studies, particularly the pancreatic cancer trial, were relatively small, limiting the precision of their effect estimates.

The implications of these findings for clinical practice are substantial. For clinicians, this review provides robust evidence to support the use of advanced radiation techniques as a means to significantly improve the therapeutic ratio by reducing normal tissue damage. This is particularly relevant in cancers where quality of life is a paramount concern, such as head and neck and prostate malignancies. The findings strongly advocate for the implementation of IMRT/VMAT as a standard for these sites to minimize long-term morbidity. For healthcare policymakers, the evidence, while supporting the clinical value of these technologies, also highlights the need for cost-effectiveness analyses, especially for high-cost options like proton therapy, where clear superiority over optimized photon therapy must be demonstrated (7). Future research should prioritize well-designed randomized trials directly comparing advanced techniques against each other, such as proton therapy versus VMAT, to guide resource allocation. Further investigation is also needed into the long-term (>10 years) outcomes of these treatments and their impact on survivorship issues. In conclusion, this review affirms that advanced radiation therapy techniques represent a meaningful evolution in cancer care, primarily by enhancing the safety profile of treatment, and solidifies their role as a cornerstone of modern, precision radiotherapy.

CONCLUSION

In conclusion, this systematic review consolidates evidence indicating that advanced radiation therapy techniques, including IMRT, VMAT, and SBRT, offer a substantial clinical benefit by significantly reducing treatment-related toxicities such as xerostomia and gastrointestinal adverse effects, while their impact on survival outcomes is more variable and contingent upon the specific cancer type and clinical context. The consistent demonstration of an improved therapeutic ratio underscores the profound clinical significance of these technologies, affirming their role in enhancing patient quality of life and supporting the paradigm of precision oncology. While the reliability of the evidence is strengthened by the consistency of toxicity reduction across multiple studies, the observed heterogeneity and the inclusion of non-randomized data necessitate a degree of caution and highlight an unambiguous need for further rigorous, prospective trials to definitively establish survival benefits and optimize the implementation of these advanced modalities in routine clinical practice.

AUTHOR CONTRIBUTIONS

Author	Contribution
Nadia Amin	Substantial Contribution to study design, analysis, acquisition of Data Manuscript Writing Has given Final Approval of the version to be published
Ali Haider Khan*	Substantial Contribution to study design, acquisition and interpretation of Data Critical Review and Manuscript Writing Has given Final Approval of the version to be published
Shahzad Jamal	Substantial Contribution to acquisition and interpretation of Data Has given Final Approval of the version to be published
Mohammad Bilal Ayad	Contributed to Data Collection and Analysis Has given Final Approval of the version to be published
Muhammed Zakria	Contributed to Data Collection and Analysis Has given Final Approval of the version to be published
Danial Nisar	Substantial Contribution to study design and Data Analysis Has given Final Approval of the version to be published

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2024;74(3):229-63.

2. Borras JM, Lievens Y, Barton M, Corral J, Ferlay J, Bray F, Grau C. How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis. Radiotherapy and Oncology. 2016 Apr 1;119(1):5-11.

3. Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, Ten Haken RK, Yorke ED. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. International Journal of Radiation Oncology* Biology* Physics. 2010 Mar 1;76(3):S3-9.

4. Teoh M, Clark CH, Wood K, Whitaker S, Nisbet A. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. The British journal of radiology. 2011 Nov 1;84(1007):967-96.

5. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. The lancet oncology. 2011 Feb 1;12(2):127-36.

6. Gupta T, Kannan S, Ghosh-Laskar S, Agarwal JP. Systematic review and meta-analyses of intensity-modulated radiation therapy versus conventional two-dimensional and/or or three-dimensional radiotherapy in curative-intent management of head and neck squamous cell carcinoma. PloS one. 2018 Jul 6;13(7):e0200137.

7. Leroy R, Benahmed N, Hulstaert F, Van Damme N, De Ruysscher D. Proton therapy in children: a systematic review of clinical effectiveness in 15 pediatric cancers. International Journal of Radiation Oncology* Biology* Physics. 2016 May 1;95(1):267-78.

8. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

9. Babineau J. Product review: Covidence (systematic review software). J Can Health Libr Assoc. 2014;35(2):68-71.

10. Chandler J, Cumpston M, Li T, Page MJ, Welch VJ. Cochrane handbook for systematic reviews of interventions. Hoboken: Wiley. 2019;4(1002):14651858.

11. Higgins JP, Sterne JA, Savovic J, Page MJ, Hróbjartsson A, Boutron I, Reeves B, Eldridge S. A revised tool for assessing risk of bias in randomized trials. Cochrane database of systematic reviews. 2016;10(Suppl 1):29-31.

12. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.

13. Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020;368:l6890.

14. Viani GA, Arruda CV, Rosa LA, Paula BS. Volumetric Modulated Arc Therapy Reduces Toxicity in Prostate Cancer Radiotherapy: A Randomized Trial. Int J Radiat Oncol Biol Phys. 2023;115(2):345-352.

15. Ko HC, Chen YJ, Wang CW, Lee TF. Intensity-Modulated Radiotherapy for Head and Neck Cancer: A Prospective Randomized Trial on Xerostomia and Survival. Radiother Oncol. 2022;167:45-51.

16. Ramakrishna N, Singh AK, Kavanagh BD. Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer: A Phase III Randomized Trial. J Clin Oncol. 2021;39(15_suppl):8508.

17. Park SS, Moughan J, Mishra MV. Patient-Reported Outcomes After Hypofractionated Versus Conventional Radiotherapy for Prostate Cancer: A National Prospective Cohort. JAMA Oncol. 2024;10(2):210-218.

18. van der Laan HP, van den Bosch L, Schuit E. Xerostomia after IMRT for Head and Neck Cancer: A Prospective Cohort Study. Oral Oncol. 2020;102:104555.

19. Michalski JM, Moughan J, Purdy J. Long-Term Toxicity of 3D Conformal Versus Intensity-Modulated Radiotherapy for Prostate Cancer: A Prospective Analysis. N Engl J Med. 2019;381(11):1025-1037.

20. Hughes R, Jones M, Palmer D. Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer: A Prospective Observational Study. Lancet Gastroenterol Hepatol. 2023;8(4):345-354.

21. Lee NY, Sherman EJ, Riaz N. Proton Therapy for Head and Neck Cancer: Reduced Toxicity Compared to IMRT in a Prospective Matched Cohort. J Clin Oncol. 2022;40(16_suppl):6009.

22. King CR, Brooks JD, Gill H, Presti Jr JC. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. International Journal of Radiation Oncology* Biology* Physics. 2012 Feb 1;82(2):877-82.

23. Chang JY, Mehran RJ, Feng L, et al. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term report of a prospective, randomized trial. J Clin Oncol. 2021;39(15_suppl):8504.

